SCHEMBL14701074

SCHEMBL14701074

Cc1oc(-c2ccccc2)nc1C(=O)Nc1ccc(C2CC2NCC2CC2)cc1

nearest known ligand 0.64

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 13/20 0.64
MAOA P21397 4/20 0.60
MAOB P27338 2/20 0.60
GAA P10253 2/20 0.60
KDM4E B2RXH2 1/20 0.60
RCOR1 Q9UKL0 6/20 0.54
SMN1; SMN2 Q16637 2/20 0.51
ALDH1A1 P00352 1/20 0.51
POLB P06746 1/20 0.48
TSHR P16473 1/20 0.48
MAPK1 P28482 1/20 0.48
RAB9A P51151 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15789220 1.00 KDM1A (0.64) KDM1AMAOAMAOBGAAKDM4E
SCHEMBL15789198 0.83 KDM1A (0.67) KDM1AMAOAMAOBRCOR1
SCHEMBL14701034 0.83 KDM1A (0.67) KDM1AMAOAMAOBRCOR1
SCHEMBL14701036 0.81 KDM1A (0.67) KDM1AMAOAMAOBRCOR1
SCHEMBL15789158 0.81 KDM1A (0.67) KDM1AMAOAMAOBRCOR1
SCHEMBL15788950 0.79 KDM1A (1.00) KDM1AMAOAMAOBRCOR1
SCHEMBL14700884 0.79 KDM1A (1.00) KDM1AMAOAMAOBRCOR1
SCHEMBL15789053 0.79 KDM1A (1.00) KDM1AMAOAMAOBRCOR1
SCHEMBL15939189 0.78 KDM1A (1.00) KDM1AMAOAMAOBRCOR1
SCHEMBL15939188 0.78 KDM1A (1.00) KDM1AMAOAMAOBRCOR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2743256-B1 CYCLOPROPANEAMINE COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2018-06-27 EP disclosed
EP-2743256-B1 CYCLOPROPANEAMINE COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2018-06-27 EP disclosed
US-9682925-B2 Cyclopropaneamine compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-06-20 US disclosed
US-9682925-B2 Cyclopropaneamine compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-06-20 US disclosed
US-20160130215-A1 CYCLOPROPANEAMINE COMPOUND TAKEDA PHARMACEUTICAL (JP) 2016-05-12 US disclosed
US-20160130215-A1 CYCLOPROPANEAMINE COMPOUND TAKEDA PHARMACEUTICAL (JP) 2016-05-12 US disclosed
US-9278931-B2 Cyclopropaneamine compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-03-08 US disclosed
US-9278931-B2 Cyclopropaneamine compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-03-08 US disclosed
US-20140228405-A1 CYCLOPROPANEAMINE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-08-14 US disclosed
US-20140228405-A1 CYCLOPROPANEAMINE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-08-14 US disclosed
EP-2743256-A1 CYCLOPROPANEAMINE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2014-06-18 EP disclosed
EP-2743256-A1 CYCLOPROPANEAMINE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2014-06-18 EP disclosed
WO-2013022047-A1 CYCLOPROPANEAMINE COMPOUND 武田薬品工業株式会社 (JP) 2013-02-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160130215-A1 CYCLOPROPANEAMINE COMPOUND KDM1A, KDM1B, KDM3A KDM1A 1/4885MAOA 101/4885MAOB 90/4885
US-20140228405-A1 CYCLOPROPANEAMINE COMPOUND KDM1A, KDM1B, KDM3A KDM1A 1/4885MAOA 101/4885MAOB 90/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.